Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology

• Main Authors: Patrick C. Bailey, Stuart S. Martin
• Format: Article
• Language: English
• Published: MDPI AG 2019-06-01
• Series: Cells
• Subjects: circulating tumor cells; CTC; liquid biopsy; CTM; CTMat; CTC biology; CTC capture technology
• Online Access: https://www.mdpi.com/2073-4409/8/6/553

Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) have been shown to correlate negatively with patient survival. Actual CTC counts before and after treatment can be used to aid in the prognosis of patient outcomes. The presence of circulating tumor materials (CTMat) can advertise the presence of metastasis before clinical presentation, enabling the early detection of relapse. Importantly, emerging evidence is indicating that cancer treatments can actually increase the incidence of CTCs and metastasis in pre-clinical models. Subsequently, the study of CTCs, their biology and function are of vital importance. Emerging technologies for the capture of CTC/CTMs and CTMat are elucidating vitally important biological and functional information that can lead to important alterations in how therapies are administered. This paves the way for the development of a “liquid biopsy” where treatment decisions can be informed by information gleaned from tumor cells and tumor cell debris in the blood.